Atrophy
36
2
4
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.6%
2 terminated out of 36 trials
91.7%
+5.2% vs benchmark
31%
11 trials in Phase 3/4
41%
9 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (36)
Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
PRF vs. Graftless Sinus Lift With Implant Placement
Investigation of Respiratory Muscle Sarcopenia in Adults Diagnosed With Diabetes
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Impact of Postprandial 'Exercise Snacks' on Protein and Glucose Metabolism Following a Period of Step Reduction in Older Adults
A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients
Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture
Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane
Extreme Lateral Interbody FusionFUSION (XLIF) Versus Posterior Lumbar Interbody Fusion (PLIF)
Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy
Effect of Blood Flow Restriction Training on Patient With Anterior Cruciate Ligament Reconstruction
Histology and Ultrasound Pilot Study of HA Gels Adipose Tissue
The Effect of Different Gingival Biotypes on Dimensional Stability of Free Gingival Graft
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
A Clinical Study to Evaluate the Safety of Ospemifene
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity